Company Encyclopedia
View More
name
PHARMARON
03759.HK
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Production Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotides, peptides, antibodies, antibody-drug conjugates (ADCs), and cell and gene therapy products; small molecule CDMO services, such as API process development and production, material science and preformulation, formulation development, and analytical development. It also provides clinical research services; macromolecular and cell and gene therapy services comprising drug discovery, development and production services, cell and gene therapy laboratory services, and gene therapy drug development and production services.
697.22 B
03759.HKMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
Life Sciences Tools and ServicesIndustry
Industry Ranking5/14
Industry medianC
Industry averageB
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE10.80%B
    • Profit Margin11.17%B
    • Gross Margin34.69%C
  • Growth ScoreB
    • Revenue YoY13.65%B
    • Net Profit YoY-20.54%D
    • Total Assets YoY7.96%B
    • Net Assets YoY6.75%B
  • Cash ScoreB
    • Cash Flow Margin895.50%B
    • OCF YoY13.65%B
  • Operating ScoreC
    • Turnover0.55C
  • Debt ScoreC
    • Gearing Ratio41.16%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Pharmaron Beijing Co. Ltd. Announces Date for First Extraordinary General Meeting of 2025

    Pharmaron Beijing Co. Ltd. will hold an extraordinary general meeting on December 18, 2025, in Beijing, China. Shareholders will vote on key resolutions, including the by-election of an independent non-executive Director and amendments to various management policies. The announcement was made via the Hong Kong Stock Exchange's Issuer Information Service.

    Reuters·
    HK
    03759
    -0.09%
    SZ
    300759
    +0.62%
    Reuters·
    HK
    03759
    -0.09%
    SZ
    300759
    +0.62%

    Pharmaron Expands CRO Market Presence with Biortus Acquisition

    Pharmaron Beijing Co., Ltd. has announced the acquisition of an 82.54% interest in Biortus, enhancing its presence in the CRO market. This acquisition, considered a connected transaction, was evaluated by comparing Biortus with four other industry companies, focusing on profitability. The move is expected to leverage Biortus' growth in revenue and profits. The latest analyst rating for Pharmaron's stock is a Buy with a HK$28.10 price target.

    Tip Ranks·
    HK
    03759
    -0.09%
    SZ
    300759
    +0.62%
    Tip Ranks·
    HK
    03759
    -0.09%
    SZ
    300759
    +0.62%

    Morning Trend | Pharmaron's capital withdrawal intensifies, is the window for pharmaceutical outsourcing revisiting?

    Pharmaron was under pressure throughout the day yesterday, with a noticeable phenomenon of capital withdrawal. The recent ratings of the pharmaceutical outsourcing industry have been downgraded, and negative fundamentals have continuously emerged, further intensifying risk aversion. The company has lost multiple short-term support levels, and the rebound efforts have been weak, with extremely scarce buying interest at low levels, ultimately closing within a weak channel. The industry news is pessimistic, with several leading outsourcing companies publicly reporting a decline in order growth and delays in overseas projects, which continue to heighten market concerns. On the technical front, the intraday suppression signals have been continuously strengthening, and there has been no significant increase in trading volume, indicating that the main funds are primarily adjusting their positions and mostly observing. The key support level of HKD 30.10 was once in jeopardy, with short sellers dominating the market and intraday risks rising. Although there is still a possibility of a short-term policy reversal or a rebound in the pharmaceutical sector driving a sharp recovery, its sustainability and strength are questionable. From an operational perspective, it is recommended to closely follow the progress of industry orders and changes in regulatory policies, and to be cautious of risks arising from rapid intraday pullbacks and unusual movements, strictly controlling positions and stop-loss measures. At this stage, it is advisable to wait for sentiment to repair and signals of main fund inflows, focusing on short-term defense

    Technical Forecast·
    SZ
    300759
    +0.62%
    HK
    03759
    -0.09%
    Technical Forecast·
    SZ
    300759
    +0.62%
    HK
    03759
    -0.09%

    Pharmaron received a pledge of 2.154 million company shares from shareholder Lou Xiaoqiang

    According to the Zhitong Finance APP, Pharmaron announced that it recently received a letter from Mr. Lou Xiaoqiang, one of the actual controllers of the company, and his concerted party Ningbo Longtaikang Investment Management Co., Ltd. (hereinafter referred to as "Longtaikang"), informing that Mr. Lou Xiaoqiang has pledged part of the shares he holds in the company, while Longtaikang has lifted the pledge on part of the shares it holds in the company. Lou Xiaoqiang pledged 2.154 million shares of the company, and Longtaikang lifted the pledge on 3.75 million shares of the company

    Zhitong·
    SZ
    300759
    +0.62%
    HK
    03759
    -0.09%
    Zhitong·
    SZ
    300759
    +0.62%
    HK
    03759
    -0.09%

    Goldman Sachs: Raises Pharmaron target price to HKD 30, last quarter's revenue slightly exceeded expectations

    Goldman Sachs raised the target price for Pharmaron's H shares to HKD 30, and the target price for A shares to RMB 38.5. The company's management has raised the full-year revenue growth guidance to 12% to 16%, expecting a year-on-year growth of 6% to 20% in the fourth quarter. Revenue for the third quarter was RMB 3.65 billion, a year-on-year increase of 13.4%. Goldman Sachs has a "Buy" rating on Pharmaron's H shares and a Neutral rating on A shares

    Zhitong·
    SZ
    300759
    +0.62%
    HK
    03759
    -0.09%
    Zhitong·
    SZ
    300759
    +0.62%
    HK
    03759
    -0.09%
    Posts
    View More

    $XTALPI(02228.HK)

    Short selling data this morning: 02228 Pharmaron (Beijing) Co., Ltd.－P 705,000 5,143,150. Average selling price 7.29

    I expect the closing price to be above this level.

    $XTALPI(02228.HK)

    Today's trend is "not good-looking". Let's look at the data, short selling:

      2228  Pharmaron－P         277,000      2,131,420

     

    This small proportion of volume is not the reason why t...

    $XTALPI(02228.HK)We should still keep playing Pharmaron recently. The US stocks are also freaking hot as hell. 😜

    • 0

    $XTALPI(02228.HK) Short interest data this morning: 2228 Pharmaron (Beijing) Co., Ltd.－P         475,000      3,516,420

     

    Average price: HK$7.4. This idiot has already lost HK$0.6 now.....

    © 2025 Longbridge｜Disclaimer